345 related articles for article (PubMed ID: 11899079)
21. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):453-5. PubMed ID: 15288367
[TBL] [Abstract][Full Text] [Related]
22. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
Reddy S; Bichler J; Wells-Knecht KJ; Thorpe SR; Baynes JW
Biochemistry; 1995 Aug; 34(34):10872-8. PubMed ID: 7662668
[TBL] [Abstract][Full Text] [Related]
23. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
[TBL] [Abstract][Full Text] [Related]
24. TAGE (toxic AGEs) hypothesis in various chronic diseases.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):449-52. PubMed ID: 15288366
[TBL] [Abstract][Full Text] [Related]
25. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW
Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546
[TBL] [Abstract][Full Text] [Related]
26. Advanced glycation end products: a Nephrologist's perspective.
Raj DS; Choudhury D; Welbourne TC; Levi M
Am J Kidney Dis; 2000 Mar; 35(3):365-80. PubMed ID: 10692262
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
28. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation.
Anderson MM; Heinecke JW
Diabetes; 2003 Aug; 52(8):2137-43. PubMed ID: 12882933
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.
Henle T; Deppisch R; Beck W; Hergesell O; Hänsch GM; Ritz E
Nephrol Dial Transplant; 1999 Aug; 14(8):1968-75. PubMed ID: 10462279
[TBL] [Abstract][Full Text] [Related]
30. Targeting advanced glycation with pharmaceutical agents: where are we now?
Borg DJ; Forbes JM
Glycoconj J; 2016 Aug; 33(4):653-70. PubMed ID: 27392438
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.
Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K
J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies.
Khalifah RG; Todd P; Booth AA; Yang SX; Mott JD; Hudson BG
Biochemistry; 1996 Apr; 35(15):4645-54. PubMed ID: 8664253
[TBL] [Abstract][Full Text] [Related]
33. Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts.
Al-Abed Y; Bucala R
Bioconjug Chem; 2000; 11(1):39-45. PubMed ID: 10639083
[TBL] [Abstract][Full Text] [Related]
34. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel advanced glycation end product derived from lactaldehyde.
Fujimoto S; Murakami Y; Miyake H; Hayase F; Watanabe H
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1136-1145. PubMed ID: 30822216
[TBL] [Abstract][Full Text] [Related]
36. Diet-derived advanced glycation end products or lipofuscin disrupts proteostasis and reduces life span in Drosophila melanogaster.
Tsakiri EN; Iliaki KK; Höhn A; Grimm S; Papassideri IS; Grune T; Trougakos IP
Free Radic Biol Med; 2013 Dec; 65():1155-1163. PubMed ID: 23999505
[TBL] [Abstract][Full Text] [Related]
37. Formation of Pentosidine Cross-Linking in Myoglobin by Glyoxal: Detection of Fluorescent Advanced Glycation End Product.
Banerjee S
J Fluoresc; 2017 Jul; 27(4):1213-1219. PubMed ID: 28299531
[TBL] [Abstract][Full Text] [Related]
38. Maillard reaction in food allergy: Pros and cons.
Gupta RK; Gupta K; Sharma A; Das M; Ansari IA; Dwivedi PD
Crit Rev Food Sci Nutr; 2018 Jan; 58(2):208-226. PubMed ID: 26980434
[TBL] [Abstract][Full Text] [Related]
39. Possible involvement of altered RGD sequence in reduced adhesive and spreading activities of advanced glycation end product-modified fibronectin to vascular smooth muscle cells.
Sakata N; Sasatomi Y; Meng J; Ando S; Uesugi N; Takebayashi S; Nagai R; Horiuchi S
Connect Tissue Res; 2000; 41(3):213-28. PubMed ID: 11264870
[TBL] [Abstract][Full Text] [Related]
40. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence.
Ahmed N; Thornalley PJ
Biochem J; 2002 May; 364(Pt 1):15-24. PubMed ID: 11988071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
